{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:25:47Z","timestamp":1772720747768,"version":"3.50.1"},"reference-count":86,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Psychiatry in Clinical Practice"],"published-print":{"date-parts":[[2000,1]]},"DOI":"10.1080\/13651500050518505","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T11:24:08Z","timestamp":1027682648000},"page":"53-61","source":"Crossref","is-referenced-by-count":6,"title":["Opportunities and challenges presented by the new generation antipsychotics"],"prefix":"10.1080","volume":"4","author":[{"given":"Jonathan S.E.","family":"Hellewell","sequence":"first","affiliation":[{"name":"Dept of Psychiatry, Trafford General Hospital, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.S.","family":"Gerlach","sequence":"additional","affiliation":[{"name":"Research Institute of Biological Psychiatry, St Hans Hospital, Roskilde, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2009,7,12]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-4042-3_4"},{"key":"e_1_2_1_3_1","volume-title":"Antipsychotic drugs and their side effects","author":"Davis JM","year":"1993","unstructured":"Davis JM, Janicak P, Singla A et al (1993) Maintenance antipsychotic medication. In Antipsychotic drugs and their side effects (ed TRE Barnes) 183-203. Academic Press, London."},{"key":"e_1_2_1_4_1","doi-asserted-by":"crossref","unstructured":"Johnstone EC Crow TJ Johnson AL et al (1986) The Northwick Park study of first episode schizophrenia: I. Presentation of the illness and problems relating to admission. Br J Psychiatry 148: 115 - 20.","DOI":"10.1192\/bjp.148.2.115"},{"key":"e_1_2_1_5_1","doi-asserted-by":"crossref","unstructured":"Beiser M Erickson D Fleming JAE et al (1993) Establishing the onset of psychotic illness. Am J Psychiatry 150: 1349 - 54.","DOI":"10.1176\/ajp.150.9.1349"},{"issue":"8","key":"e_1_2_1_6_1","author":"Loebel AD","year":"1992","unstructured":"Loebel AD, Lieberman JA, Alvir JMJ et al (1992) Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149: 1183 - 8.","journal-title":"Alvir JMJ"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800250095013"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","unstructured":"Kane J Honigfeld G Singer J et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with clozapine. Arch Gen Psychiatry 45: 789 - 96.","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_2_1_9_1","doi-asserted-by":"crossref","unstructured":"Tollefson GD Kuntz AJ (1999) Review of recent clinical studies with olanzapine. Br J Psychiatry 175 (suppl 37): 30 - 35.","DOI":"10.1192\/S0007125000293641"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","unstructured":"Hamilton SH Revicki DA Genduso LA et al (1998) Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsycho- pharmacology 18: 41 - 49.","DOI":"10.1016\/S0893-133X(97)00111-5"},{"key":"e_1_2_1_11_1","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder SR","year":"1994","unstructured":"Marder SR, Meibach RL (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825 - 35.","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_12_1","doi-asserted-by":"crossref","unstructured":"Arvanitis LA Miller BG and the Seroquel Trial 13 study group (1997) Multiple fixed doses of `Seroquel\u2019 (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233 - 46.","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"e_1_2_1_13_1","doi-asserted-by":"crossref","unstructured":"Small JO Hirsch SR Arvanitis LA and the Seroquel Study Group (1997) Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54: 549 - 57.","DOI":"10.1001\/archpsyc.1997.01830180067009"},{"key":"e_1_2_1_14_1","doi-asserted-by":"crossref","unstructured":"Bondolfi G Dufour H Patris M et al (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomised double-blind study. Am J Psychiatry 155: 499 - 504.","DOI":"10.1176\/ajp.155.4.499"},{"key":"e_1_2_1_15_1","doi-asserted-by":"crossref","unstructured":"Flynn SW MacEwan GW Altman S et al (1998) An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 31: 25 - 29.","DOI":"10.1055\/s-2007-979291"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00291-1"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/23.4.663"},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","unstructured":"Emsley RA Raniwalla J Bailey PJ et al (2000) A comparison of the effects of quetiapine (`Seroquel\u2019) and haloperidol in schizophrenic patients with a history of and a demonstrated partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 15: 121 - 31.","DOI":"10.1097\/00004850-200015030-00001"},{"key":"e_1_2_1_19_1","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizo- affective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson GD","year":"1997","unstructured":"Tollefson GD, Beasley CM, Tran P (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizo- affective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457 - 65.","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_20_1","doi-asserted-by":"crossref","unstructured":"Song F (1997) Risperidone in the treatment of schizophrenia: a meta-analysis of randomised controlled trials. J Psychopharmacol 11: 65 - 71.","DOI":"10.1177\/026988119701100116"},{"key":"e_1_2_1_21_1","article-title":"Review of quetiapine and its clinical applications in schizophrenia","volume":"1","author":"Kasper S","year":"2000","unstructured":"Kasper S, Muller-Spahn F (2000) Review of quetiapine and its clinical applications in schizophrenia. Exp Opin Pharma- cotherapy 1: 783 - 801.","journal-title":"Exp Opin Pharma- cotherapy"},{"key":"e_1_2_1_22_1","article-title":"A path analytic double-blind, placebo and haloperidol controlled clinical trial with olanzapine","volume":"154","author":"Tollefson GD","year":"1997","unstructured":"Tollefson GD, Sanger TM (1997) A path analytic double-blind, placebo and haloperidol controlled clinical trial with olanzapine. Am J Psychiatry 154: 466 - 74.","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_23_1","unstructured":"Tandon R Haddad P (2000) Atypical antipsychotics have equivalent efficacy in treating negative symptoms of schizo- phrenia. Int J Neuropsychopharmacol 3 (suppl 1): S159 - S160."},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442559"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(98)00023-5"},{"issue":"8","key":"e_1_2_1_26_1","article-title":"Akathisia variants and tardive dyskinesia","volume":"42","author":"Barnes TRE","year":"1985","unstructured":"Barnes TRE, Braude WM (1985) Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42: 874 - 8.","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_2_1_27_1","doi-asserted-by":"crossref","unstructured":"Burke RE Kang UK Jankovic J et al (1989) Tardive dyskinesia: an analysis of clinical features and response to open therapeutic trials. Movement Dis 4: 157 - 75.","DOI":"10.1002\/mds.870040208"},{"key":"e_1_2_1_28_1","doi-asserted-by":"crossref","unstructured":"Tollefson GD Beasley CM Tamura RN et al (1997) Blind controlled long term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psycch 154: 1248 - 54.","DOI":"10.1176\/ajp.154.9.1248"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)90811-9"},{"key":"e_1_2_1_30_1","article-title":"A literature review of prolactin in schizophrenia","volume":"1","author":"Peuskens J","year":"1997","unstructured":"Peuskens J (1997) A literature review of prolactin in schizophrenia. Clear Perspecives 1(2): 1 - 36.","journal-title":"Clear Perspecives"},{"key":"e_1_2_1_31_1","doi-asserted-by":"crossref","unstructured":"Prentice DS Deakin JFW (1992) Role of neuroleptic drugs and organic mechanisms in the aetiology of menstrual irregularities in schizophrenic women. Schizophr Res 6(2) (special issue) 114.","DOI":"10.1016\/0920-9964(92)90144-T"},{"issue":"1","key":"e_1_2_1_32_1","article-title":"Do we know what matters to our patients? In","volume":"2","author":"Hellewell JSE","year":"1999","unstructured":"Hellewell JSE (1999) Do we know what matters to our patients? In Approaches to schizophrenia communication: strategies for the early recognition and effective treatment of antipsychotic side- effects. Clear Perspectives 2(4): 1 - 4.","journal-title":"Approaches to schizophrenia communication: strategies for the early recognition and effective treatment of antipsychotic side- effects. Clear Perspectives"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/13651509709024734"},{"key":"e_1_2_1_34_1","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan JT","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, et al (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharma- cokinet 37: 177 - 93.","journal-title":"Clin Pharma- cokinet"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/13651509909024770"},{"key":"e_1_2_1_36_1","article-title":"Patients\u2019 satisfaction with antipsychotic drug therapy for schizophrenia","volume":"2","author":"Voruganti LNP","year":"1999","unstructured":"Voruganti LNP (1999) Patients\u2019 satisfaction with antipsychotic drug therapy for schizophrenia. Clear Perspectives 2(3): 7 - 12.","journal-title":"Clear Perspectives"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199609000-00001"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199711010-00005"},{"key":"e_1_2_1_39_1","volume-title":"The side effects of antipsychotic drugs","author":"Barnes TRE","year":"1993","unstructured":"Barnes TRE, Edwards JG (1993) The side effects of antipsychotic drugs. 1. CNS and neuromuscular affects. In Antipsychotic drugs and their side-effects (ed TRE Barnes) 213 - 247. Academic Press, London."},{"key":"e_1_2_1_40_1","unstructured":"Lieberman JA Jody D Geisler S et al (1989) Treatment outcome of first episode schizophrenia. Psychopharmacol Bull 25: 92 - 96."},{"key":"e_1_2_1_41_1","doi-asserted-by":"crossref","unstructured":"Morrison AP Bowe S Larkin W et al (1999) The psychological impact of psychiatric admission: some preliminary findings. J Nerv Ment Dis 187: 250 - 3.","DOI":"10.1097\/00005053-199904000-00011"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1981.01780270073010"},{"key":"e_1_2_1_43_1","first-page":"12","volume-title":"Spontaneous and drug-induced movement disorders in schizophrenia","author":"Kopala LC","year":"1996","unstructured":"Kopala LC (1996) Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand (Suppl 1): 389: 12 - 17."},{"key":"e_1_2_1_44_1","doi-asserted-by":"crossref","unstructured":"Kopala LC Baldwin D Weiden P et al (1999) Overcoming challenges in the management of schizophrenia. Int J Psych Clin Pract 3: 11 - 15.","DOI":"10.3109\/13651509909024753"},{"key":"e_1_2_1_45_1","doi-asserted-by":"crossref","unstructured":"Brenner HD Dencker SJ Goldstein MJ et al (1990) Defining treatment refractoriness in schizophrenia. Schizophr Bull 16: 551 - 61.","DOI":"10.1093\/schbul\/16.4.551"},{"key":"e_1_2_1_46_1","unstructured":"Hellewell JSE (1999) Treatment resistant schizophrenia: reviewing the options. J Clin Psych 60 (suppl 23): 14 - 19."},{"key":"e_1_2_1_47_1","article-title":"Commentary: defining treatment refractoriness in schizophrenia","volume":"16","author":"Meltzer HY","year":"1992","unstructured":"Meltzer HY (1992) Commentary: defining treatment refractoriness in schizophrenia. Schizophr Bull 16: 563 - 5.","journal-title":"Schizophr Bull"},{"key":"e_1_2_1_48_1","article-title":"High-dose chlorpromazine therapy in chronic schizophrenia","volume":"18","author":"Prien RF","year":"1968","unstructured":"Prien RF, Cole JO (1968) High-dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 18: 482 - 95.","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_2_1_49_1","article-title":"Effects of clozapine on positive and negative symptoms in out-patients with schizophrenia","volume":"151","author":"Breier A","year":"1994","unstructured":"Breier A, Buchanan RW, Kirkpatrick B (1994) Effects of clozapine on positive and negative symptoms in out-patients with schizophrenia. Am J Psychiatry 151: 2 - 26.","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1977.01770150055005"},{"key":"e_1_2_1_51_1","doi-asserted-by":"crossref","unstructured":"Curson DA Barnes TR Bamber RW et al (1985) 7-year follow up of the MRC `Modecate\u2019 trial. Br J Psychiatry 146: 464 - 80.","DOI":"10.1192\/bjp.146.5.464"},{"key":"e_1_2_1_52_1","doi-asserted-by":"crossref","unstructured":"Barnes TR Curson DA Liddle PF et al (1989) The nature and prevalence of depression in chronic schizophrenia in-patients. Br J Psychiatry 154: 486 - 91.","DOI":"10.1192\/bjp.154.4.486"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(18)30644-0"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/16.4.571"},{"issue":"5","key":"e_1_2_1_55_1","article-title":"Suicides in schizophrenics","volume":"35","author":"Tsuang MT","year":"1978","unstructured":"Tsuang MT (1978) Suicides in schizophrenics. Arch Gen Psychiatry 35: 153 - 5.","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_2_1_56_1","volume-title":"Antipsychotic drugs and their side effects","author":"Johnson DAW","year":"1993","unstructured":"Johnson DAW (1993) Depot neuroleptics. In Antipsychotic drugs and their side effects (ed. TRE Barnes) 205 - 12. Academic Press, London."},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/17.1.75"},{"key":"e_1_2_1_58_1","article-title":"EPS: subjective and mental aspects and their impact on outcome","volume":"2","author":"Tandon R","year":"1999","unstructured":"Tandon R, Jibson MD, DeQuardo JR (1999) EPS: subjective and mental aspects and their impact on outcome. Clear Perspectives 2(3): 13 - 17.","journal-title":"Clear Perspectives"},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810350018003"},{"key":"e_1_2_1_60_1","article-title":"Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment","volume":"152","author":"Meltzer HY","year":"1995","unstructured":"Meltzer HY, Okayli G (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152: 183 - 90.","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_61_1","article-title":"Suicide attempts associated with akathisia","volume":"142","author":"Drake RE","year":"1985","unstructured":"Drake RE, Ehrlich J (1985) Suicide attempts associated with akathisia. Am J Psychiatry 142: 499 - 501.","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.3.250"},{"key":"e_1_2_1_63_1","article-title":"Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine","volume":"11","author":"Khouzman HR","year":"2000","unstructured":"Khouzman HR (2000) Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine. Depress Anxiety 11: 80 - 82.","journal-title":"Depress Anxiety"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(18)30175-8"},{"key":"e_1_2_1_65_1","doi-asserted-by":"crossref","unstructured":"Saykin AJ Gur RC Gur RE et al (1991) Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 48: 618 - 24.","DOI":"10.1001\/archpsyc.1991.01810310036007"},{"key":"e_1_2_1_66_1","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green MF","year":"1996","unstructured":"Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321 - 30.","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(97)00010-8"},{"key":"e_1_2_1_68_1","doi-asserted-by":"crossref","unstructured":"Cassens G Inglis AK Applebaum PS et al (1990) Effects on neuropsychological function in chronic schizophrenia patients. Schizophr Bull 16: 477 - 99.","DOI":"10.1093\/schbul\/16.3.477"},{"key":"e_1_2_1_69_1","article-title":"Cognitive function in schizophrenia: do neuroleptics make a difference?","volume":"56","author":"Mortimer AM","year":"1996","unstructured":"Mortimer AM (1996) Cognitive function in schizophrenia: do neuroleptics make a difference? Pharmacol Biochem Behav 56: 789 - 95.","journal-title":"Pharmacol Biochem Behav"},{"key":"e_1_2_1_70_1","article-title":"The effects of clozapine on neurocognition: an overview","volume":"55","author":"Goldberg TE","year":"1994","unstructured":"Goldberg TE, Weinberger DR (1994) The effects of clozapine on neurocognition: an overview. J Clin Psychiatry 55: 88 - 90.","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_71_1","article-title":"Does risperidone improve verbal working memory in treatment- resistant schizophrenia?","volume":"154","author":"Green MF","year":"1997","unstructured":"Green MF, Marshall Jr BD, Wirshing WC (1997) Does risperidone improve verbal working memory in treatment- resistant schizophrenia? Am J Psychiatry 154: 799 - 804.","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_72_1","doi-asserted-by":"crossref","unstructured":"Purdon SE (1999) Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 35 (suppl): S51 - S60.","DOI":"10.1016\/S0920-9964(98)00166-2"},{"key":"e_1_2_1_73_1","volume-title":"Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment","author":"Velligan DI","year":"1999","unstructured":"Velligan DI, Miller AL (1999) Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 60 (suppl 23): 25 - 28."},{"key":"e_1_2_1_74_1","volume-title":"American College of Neuropsycho- pharmacology Annual Meeting, Acapulco, Mexico","author":"Velligan DI","year":"1999","unstructured":"Velligan DI, Newcomer J, Pultz J et al (1999) Changes in cognitive functioning with quetiapine fumurate versus haloperidol. Abstract, American College of Neuropsycho- pharmacology Annual Meeting, Acapulco, Mexico."},{"key":"e_1_2_1_75_1","article-title":"A controlled dose comparison of haloperidol in newly admitted schizophrenic patients","volume":"48","author":"Van Putten T","year":"1991","unstructured":"Van Putten T, Marder SR, Mintz J (1991) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 48: 166 - 70.","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_2_1_76_1","doi-asserted-by":"crossref","unstructured":"Rifkin A Doddi S Karajgi B et al (1991) Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48: 166 - 70.","DOI":"10.1001\/archpsyc.1991.01810260074011"},{"key":"e_1_2_1_77_1","doi-asserted-by":"crossref","unstructured":"Reardon GT Rifkin A Schwartz A et al (1989) Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry 146: 726 - 29.","DOI":"10.1176\/ajp.146.6.726"},{"key":"e_1_2_1_78_1","volume-title":"Schizophrenia","author":"Barnes TRE","year":"1995","unstructured":"Barnes TRE, Hirsch SR (1995) The clinical treatment of schizophrenia with antipsychotic medication. In Schizophrenia (eds SR Hirsch, DR Weinberger) 443 - 68. Blackwell, Oxford."},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/23.4.663"},{"key":"e_1_2_1_80_1","doi-asserted-by":"crossref","unstructured":"Casey DE (1997) Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? Int Clin Psychopharmacol 12 (suppl 1): S19 - S27.","DOI":"10.1097\/00004850-199702001-00004"},{"key":"e_1_2_1_81_1","unstructured":"Meltzer H Goode DJ Schyve PM et al (1979) Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1: 28 - 36."},{"key":"e_1_2_1_82_1","doi-asserted-by":"crossref","unstructured":"Kemp R Kirov G Everitt B et al (1998) Randomised controlled trial of compliance therapy: 18 month follow-up. Br J Psychiatry 172: 413 - 19.","DOI":"10.1192\/bjp.172.5.413"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651500050518028"},{"key":"e_1_2_1_84_1","article-title":"Switching between clozapine and risperidone treatment","volume":"42","author":"Gardener DM","year":"1997","unstructured":"Gardener DM (1997) Switching between clozapine and risperidone treatment. Can J Psychiatry 42: 430 - 1.","journal-title":"Can J Psychiatry"},{"issue":"10","key":"e_1_2_1_85_1","article-title":"Dosing the antipsychotic medication olanzapine","volume":"58","author":"Nemeroff CB","year":"1997","unstructured":"Nemeroff CB (1997) Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 58 (Suppl 10): 45 - 49.","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199710000-00022"},{"key":"e_1_2_1_87_1","article-title":"Neuroleptics and sexual functioning","volume":"4","author":"Lehman HE","year":"1986","unstructured":"Lehman HE (1986) Neuroleptics and sexual functioning. Integr Psychiatry 4: 96 - 108.","journal-title":"Integr Psychiatry"}],"container-title":["International Journal of Psychiatry in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13651500050518505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:10:36Z","timestamp":1772716236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13651500050518505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1080\/13651500050518505"],"URL":"https:\/\/doi.org\/10.1080\/13651500050518505","relation":{},"ISSN":["1365-1501","1471-1788"],"issn-type":[{"value":"1365-1501","type":"print"},{"value":"1471-1788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1]]}}}